Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (603707.SS) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-26). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. 603707.SS files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.69% | 30.00% | Pass |
| Interest-bearing investments | 19.93% | 30.00% | Pass |
| Non-permissible income | 0.47% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 23.26% | 33.00% | Pass |
| Interest-bearing investments | 26.21% | 33.00% | Pass |
| Non-liquid assets | 62.03% | at least 20.00% | Pass |
| Non-permissible income | 0.47% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 23.26% | 33.33% | Pass |
| Cash + interest-bearing securities | 26.21% | 33.33% | Pass |
| Accounts receivable | 37.97% | 33.33% | Fail |
| Non-permissible income | 0.47% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 23.26% | 33.33% | Pass |
| Cash + interest-bearing securities | 26.21% | 33.33% | Pass |
| Accounts receivable | 37.97% | 50.00% | Pass |
| Non-permissible income | 0.47% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.26% | 33.00% | Pass |
| Cash + interest-bearing securities | 13.81% | 33.00% | Pass |
| Accounts receivable | 6.20% | 33.00% | Pass |
| Non-permissible income | 0.47% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.57% | 33.00% | Pass |
| Cash + interest-bearing securities | 13.04% | 49.00% | Pass |
| Accounts receivable | 5.85% | 49.00% | Pass |
| Non-permissible income | 0.47% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 11.57% | 33.33% | Pass |
| Cash + interest-bearing securities | 13.04% | 33.33% | Pass |
| Accounts receivable | 18.89% | 49.00% | Pass |
| Non-permissible income | 0.47% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 39.00 | NEUTRAL |
| Stochastic %K (14) | 4.04 | BUY |
| CCI (20) | -191.41 | BUY |
| Williams %R (14) | -95.96 | BUY |
| MACD (12,26,9) | -0.07 | SELL |
| ROC (10) | -4.87 | SELL |
| Momentum (10) | -0.38 | SELL |
| EMA (10) | 7.77 | SELL |
| SMA (10) | 7.85 | SELL |
| EMA (20) | 7.88 | SELL |
| SMA (20) | 7.95 | SELL |
| EMA (30) | 7.91 | SELL |
| SMA (30) | 8.01 | SELL |
| EMA (50) | 7.94 | SELL |
| SMA (50) | 7.92 | SELL |
| EMA (100) | 8.17 | SELL |
| SMA (100) | 8.03 | SELL |
| EMA (200) | 8.80 | SELL |
| SMA (200) | 8.76 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceutical raw materials and preparations in China and internationally. The company offers generics for oncology, critical care, IVF, and diabetes; and standard heparin preparations and low molecular weight heparin preparations, including enoxaparin sodium injections, dalteparin sodium injection, and nadroparin calcium injection. It also provides non-heparin sterile injections, such as adalimumine injection, paclitaxel injection, liraglutide injection, daptomycin for injection, pantoprazole sodium for injection, reganoxone injection, leucovorin calcium for injection, bivalirudin for injection, micafungin for injection, ducalciferol injection, fondaparinux sodium injection, and cisatracurium besylate injection. In addition, the company offers process development and preparation, process optimization, registration and validation approval, and manufacturing, as well as customized research and development, and manufacturing for commercialization. Its injection products are used in anticoagulation, anti-tumor, and cardiovascular disease areas, surgical anesthesia, antibacterial infection, and contrast imaging. The company was founded in 2000 and is based in Nanjing, China.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.